Astellas is committed to providing timely and accurate information about our business, science and products. This section offers local resources for investors, journalists and media professionals. Global news and resources can be viewed here. If you are not an investor or journalist, click here.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
DEERFIELD, IL, October 14, 2008 – Astellas Pharma US, Inc., a leader in the field of transplantation, has announced the winners of the fourth annual Astellas Ride of a Lifetime contest. Launched...
SOUTH SAN FRANCISCO, Calif. & MELVILLE, N.Y.-- Genentech, Inc. (NYSE:DNA) and OSI Pharmaceuticals, Inc. (Nasdaq:OSIP) today announced that a randomized Phase III study (BeTa Lung) evaluating Avastin®
Greater Chicago-area science teachers gain resources to inspire young scientists in the classroom DEERFIELD, IL, October 1, 2008 – Astellas Pharma US, Inc. (“Astellas”) is pleased to...
Vancouver, Canada and Deerfield, Illinois, USA, August 11, 2008 -- Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) and its co-development partner Astellas Pharma US, Inc. (“Astellas”) today...
Read more about Cardiome and Astellas Announce Receipt of FDA Approvable Letter for Kynapid™
First A2A Adenosine Receptor Agonist Approved for Use in Identifying Coronary Artery Disease Deerfield, Ill., June 24, 2008 – Astellas Pharma US, Inc. today announced the commercial availability...
First A2A Adenosine Receptor Agonist Approved for Use as Pharmacologic Stress Agent in Myocardial Perfusion Imaging PALO ALTO, Calif. and DEERFIELD, Ill., April 10 /PRNewswire-FirstCall/ -- CV...
Deerfield, Illinois and Vancouver, Canada, March 25, 2008 -- Astellas Pharma US, Inc. and its co-development partner Cardiome Pharma Corp. announced the first pivotal Phase III study evaluating...
MELVILLE, N.Y.--(BUSINESS WIRE)--Feb. 27, 2008--OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) announced today that it has filed with the U.S. Patent and Trademark Office an application to reissue its...
PRNewswire DEERFIELD, Ill. Astellas Pharma Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved their Supplemental New Drug Application (sNDA) seeking approval for...
Read more about FDA Approves Additional Indication for Astellas' MYCAMINE®
Vancouver, Canada and Deerfield, Illinois, USA, January 21, 2008 -- Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) and its co-development partner Astellas Pharma US, Inc. (“Astellas”) today...
Read more about Cardiome and Astellas Announce Regulatory Update
MELVILLE, N.Y.--(BUSINESS WIRE)--Dec. 14, 2007--OSI Pharmaceuticals, Inc. (Nasdaq: OSIP) announced today that Tarceva® (erlotinib) has been listed on Japan's National Health Insurance (NHI) drug...
Read more about OSI Pharmaceuticals Announces Launch Date of Tarceva(R) (erlotinib) in Japan
Vancouver, Canada and Deerfield, Illinois, USA, December 11, 2007 -- Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) and its co-development partner Astellas Pharma US, Inc. (“Astellas”) today...
Read more about FDA Advisory Committee Recommends Approval of Kynapid™ for Acute Atrial Fibrillation
ORLANDO, FL – November 7, 2007 – Astellas Pharma US, Inc. today announced that the investigational agent vernakalant hydrochloride increased conversion to normal heart rhythm (sinus rhythm, or...
Deerfield, Illinois – October 25, 2007 – Astellas Pharma US, Inc. today announced data demonstrating that VAPRISOL® (conivaptan hydrochloride injection) effectively raises serum sodium...
BASEL, Switzerland & MELVILLE, N.Y.--(BUSINESS WIRE)--Oct. 22, 2007--Roche and OSI Pharmaceuticals, Inc. (Nasdaq: OSIP) announced today that Tarceva® (erlotinib) has been approved in Japan for...
Read more about Tarceva(R) (erlotinib) Earns Approval for Lung Cancer Patients in Japan
SOUTH SAN FRANCISCO, CA and DEERFIELD, IL/OCTOBER 22, 2007 – Theravance, Inc. (NASDAQ: THRX) and Astellas Pharma US, Inc. announced today that the U.S. Food and Drug Administration (FDA) issued...
Educational program offers unique resources to empower transplant patients and their caregivers DEERFIELD, IL, October 17, 2007 – Astellas Pharma US, Inc., a leader in the field of...
Reaffirms 2007 Global Tarceva Sales Guidance MELVILLE, N.Y.--(BUSINESS WIRE)--Oct. 15, 2007--OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) provided commentary today on third quarter U.S. Tarceva sales....
Read more about OSI Pharmaceuticals Provides Additional Information about US Sales of Tarceva
DEERFIELD, IL, October 11, 2007 – Astellas Pharma US, Inc., a leader in the field of transplantation, has announced the winners of the third annual Astellas Ride of a Lifetime contest. Launched...
MELVILLE, N.Y.--(BUSINESS WIRE)--Sept. 18, 2007--OSI Pharmaceuticals, Inc. (Nasdaq: OSIP) announced today that the Company has received Notice of Final Determination from the US Patent and...
Read more about OSI Pharmaceuticals Announces Patent Term Extension for Tarceva(R) (erlotinib)
MELVILLE, N.Y., Sep 07, 2007 (BUSINESS WIRE) -- OSI Pharmaceuticals, Inc. (Nasdaq: OSIP) today provided a summary of selected data from over 58 studies involving the Company's lead product,...
CHICAGO--(BUSINESS WIRE)--June 5, 2007--OSI Pharmaceuticals, Inc. (Nasdaq: OSIP) today provided a summary of studies highlighting data involving the Company's lead product, Tarceva®, presented...
MELVILLE, N.Y.--(BUSINESS WIRE)--April 25, 2007--OSI Pharmaceuticals, Inc. (Nasdaq: OSIP) announced today that results published yesterday in the Journal of Clinical Oncology show that adding...
Arginine vasopressin (AVP) receptor antagonist now approved for the management of the two most common forms of potentially life-threatening sodium/water imbalance DEERFIELD, Illinois, March 2,...
Read more about FDA Approves Astellas' Vaprisol® for the Treatment of Hypervolemic Hyponatremia
Multi-award winning program offers resources to empower transplant patients and their caregivers DEERFIELD, IL, February 26, 2007 – Astellas Pharma US, Inc., a leader in the field of...
Follow U.S. news
